www.eubiologics.com



EuBiologics Co., Ltd. www.eubiologics.com

Main Office in Seoul 6F Bomnal-A-Chim B/D, Mabang-ro 8, Seocho-gu, Seoul, 06778, South Korea Tel. +82-2-572-6675 Fax. +82-2-574-6678

Bio-Plant, R&D Center in Chuncheon

3-3, 4-dong, BiovenchurePlaza, Soyanggang-ro 56, Chuncheon-si, Gangwon-do, 24232, South Korea Tel. +82-33-817-4001 Fax. +82-33-817-4002







EuBiologics Co., Ltd.

eubiolog

EuBiologics Co., Ltd.

EuBiologics Co., Ltd. is a privately-held Korean biopharmaceutical company providing contract research and manufacturing services to domestic and international clients. In addition to building a portfolio of vaccines designed to improve global public health, the company was established with the objective of becoming a preferred strategic partner providing solutions for the development and manufacturing of biopharmaceutical products.

The company is capable of manufacturing a variety of mammalian cell and microbe-derived, protein based therapeutics and antibodies. It provides customized services to various stages of product development, including cell banking, GMP production, validation and regulatory support.

The company has licensed in the manufacturing technology necessary to produce an oral cholera vaccine from the International Vaccine Institute and worked on the development of a safe and effective oral cholera vaccine, Euvichol for global public market. Euvichol was accredited by obtaining WHO prequalification in 2015.

Our mission is "For health that lasts a lifetime" and the vision is "To be a global biopharmaceutical company providing safety, health and lively future" For additional information about the company, please visit http://www.eubiologics.com/ENG/

Qualification of CRM₁₉₇

CRM₁₀₇ is a genetically detoxified form of diphtheria toxin that has been successfully and widely used as a carrier protein for developing carbohydrate conjugated vaccines.

CRM₁₀₇ has also been reported as an anti-cancer factor that binds and inhibits EGF receptor heparinbinding epidermal growth factor-like growth factor (HB-EGF), which is overexpressed in cancer cells.

EuBiologics has established a highly productive CRM₁₉₇ manufacturing process by growing C. diphtheriae in order to use this protein not only for the production of conventional vaccines but also for cancer immunotherapeutics development. The qualification of CRM₁₉₇ was fulfilled through analysis of characteristics (SDS-PAGE, western blot (not shown), SEC-HPLC analysis, circular dichroism and so on).



CRM₁₉₇ Product Details

- Native CRM₁₉₇ by C. diphtheriae strain
- High yield of CRM₁₉₇
- **High purity of CRM**₁₉₇
- Not very expensive but high quality

Source

· Corynebacterium diphtheriae

Species

· Corynebacterium diphtheriae

Product list

- 0.2 mg/vial
- 0.5 mg/vial
- 1.0 mg/vial

Formulation

- Each vial contains 0.2/0.5/1.0 mg of CRM₁₀₇, a non-toxic mutant of diphtheria toxin.
- 21 mM sodium phosphate dibasic, 5% sucrose, 0.005% polysorbate 80, pH 7.4.

Concentration

· Protein concentration was determined by Bradford assay using bovine serum albumin as the standard.

Purity

- The purity of the product was estimated as > 95% by densitometric and SEC-HPLC analysis.
- The endotoxin content determined using a kinetic chromogenic LAL assay was <1 EU/µg.

Storage

• This preparation is provided as a lyophilized powder. Before reconstitution, it should be stored at 2-8°C For extended storage, it is recommended to store in aliquots at -20° C to -80° C are not recommended.

Use

- Before use, reconstitute lyophilized powder with sterile deionized water to a concentration of 0.2/0.5/1.0 mg/mL CRM₁₀₇.
- Handle the product gently, do not vortex. Reconstituted CRM₁₀₇ should be stored at 2-8°C
- FOR RESEARCH USE ONLY and NOT FOR HUMAN USE.

References

- 1. Giannini G et. al., Nucleic Acids Res. 12: 4063-4069 (1984)
- 2. Malito E et. al., Proc Natl Acad Sci U S A. 109 (2012) 5229-5234
- 3. Dateoka S et. al., Med Mol Morphol. 45 (2012) 91-97



• When reconstituted with 1 mL sterile deionized water, the protein is in 1.8 mM sodium phosphate monobasic,

*NOTE: Repeated freezing and thawing or maintaining the preparation at 2-8 °C for extended periods of time